cyrilzakka/clinical-trials huggingface dataset:
Artificial Intelligence Analysis of Initial Scan Evolution of Traumatic Brain Injured Patient to Predict Neurological Outcome

We assume that an early iterative automatic CT scan analysis (D0, D1 and D3) by different AI approaches will allow an early differentiation of the tissues evolution after TBI. Our objective is to couple theses scan profiles to a neurological evolution, measured by therapeutic intensity.

Traumatic brain injury is a common and serious pathology, responsible of an important morbi-mortality. The TBI can be consider as a complex set of nosological entities of different evolution with difficult early identification whereas the main issue of this pathology depends on prevention and management of the lesions caused by the initial cerebral aggression.

Different evolutionary profiles seems to exist and sometimes coexists: edema evolution, hemorrhagic transformation and/or cerebrospinal fluid (CSF) resorption issues with hydrocephalus apparition.

Currently, there is no Imaging methods that can be used in every day clinical management that allows a visualization, quantification and prediction of these different lesional evolutions

CT scan is the reference imaging method for TBI patient monitoring. It allows a lesion description, a therapeutic adaptation and an evaluation of the prognostic.

Even if it is used as a routine examination, the analysis of cerebral scanners remains manual and a non-quantitative one, which make a little informative analysis as far as lesions evolution is concerned.

Recently it has been established the automatic MRI analysis with AI approach allows:

1. - To show aspects of images that can't be seen to the naked eye
2. - To automatically segment and quantify the different tissues (edema, hemorrhage...). First tests on this kind of analysis on CT scans shows that this technology can be transferred from MRI to CT scans and more importantly it brings out new quantitative informations on cerebral lesions evolution.

Eligibility Criteria:
Inclusion Criteria:

* Age \> or = 18 years old
* Closed TBI
* Primary admission in Grenoble University Hospital
* Initial CT scan with visible cerebral lesion rated at least 3 on abbreviated injury score (AIS)
* In ICU for an expected length of 48 hours
* Social security system affiliation

Exclusion Criteria:

* Life expectation \<48 hours
* In ICU for more than 24h
* Transferred from another hospital
* Patients corresponding to articles L1121-5, L1121-6, L1121-7, L1121-8 (under legal protection) of French Public Health Code
* Patient in exclusion time of another study
Validation of a Method to Measure Soft Tissue Thickness Using Near Infrared Laser Light

The study is intended to verify a newly developed method to measure the thickness of cranial soft tissue. In the study, a high-resolution MRI scan is used as ground truth for a laser scan of the forehead. The laser scan is acquired point by point with a prototype scanning unit developed at the University of Luebeck's Institute for Robotics.

The measured tissue thickness using the near-infrared scanning approach is validated against the ground truth obtained by the MRI scan. The average accuracy of the reconstruction method is then computed over all subjects from the individual study arms.

The required laser intensity and exposure time as well as the achieved measurement accuracy is evaluated with respect to the different skin types of the test subjects. Correlation between these features and the skin type according to the Fitzpatrick scale will be computed.

For 1/3 of the subjects, the laser and MRI scans are repeated after 2 and 8 weeks. The results of the scans are compared and time dependency is analysed.


Eligibility Criteria:
Inclusion Criteria:

* male and female adults
* variations in skin type (at least 10 subjects with skin types I \& II, at least 2 subjects with skin type III, at least 3 subjects with skin type IV, at least 3 subjects with skin types V \& VI)
* optional: availability of high-resolution CT or CBCT (cone-beam CT) scan of the forehead

Exclusion Criteria:

* allergies or intolerances against ABS (acrylonitrile butadiene styrene), PMMA (polymethyl methacrylate) or alginate
* elevated light sensitivity of the skin
* exclusion criteria for MRI (claustrophobia, motoric disorders, tattoos, body piercings, metallic implants in the skull, epilepsy, cardiac pacemakers)
Efficacy and Safety Study of Pregabalin in the Treatment of Pain on Walking in Patients With Diabetic Peripheral Neuropathy (DPN)

The intent of this study is to treat subjects with painful Diabetic Peripheral Neuropathy (DPN) who also have pain on walking and to determine whether or not pregabalin demonstrates improvement relative to placebo on the following: reducing DPN pain, reducing pain on walking, and providing other benefits associated with daily activities and quality of life.


Eligibility Criteria:
Inclusion Criteria:

* Men or women who are at least 18 years old.
* Diagnosis of painful diabetic peripheral neuropathy.
* Pain on walking.

Exclusion Criteria:

* Inability to walk 50 feet on a flat surface.
* Pain on walking due to conditions other than diabetic peripheral neuropathy.
Clinical Assessment Of Age-related Macular Degeneration Patients After Early Diagnosis and Treatment With Ranibizumab

To determine if patients treated early after diagnosis of wet age-related macular degeneration can return/maintain to their baseline pre-disease BCVA.

We will conduct an open label, multi-center study of naïve AMD patients that are identified early upon disease progression (had a normal VA, FA or OCT within 4 months prior to entry) to assess if treating with ranibizumab monthly can restore all patients to their baseline vision pre-AMD. Recent randomized clinical trials (MARINA, ANCHOR) have conclusively demonstrated that continued intravitreal therapy with ranibizumab in patients with subfoveal CNV from AMD leads to stabilization of vision in over 90% of patients and improvement in vision in at least a third of the patients and has led to the approval of ranibizumab (0.5 mg) for the treatment of neovascular AMD.

Patients will receive monthly intravitreal ranibizumab injections for 12 months (with dose holding for return to baseline/ 20/20 or better and no evidence of fluid on SD-OCT or FA). All patients will have ETDRS vision and SD-OCT, and complete exam at each monthly visit. Patients will each have a blood analysis for genetics (either during the GALLEY study in which they converted to wet AMD and entered COMPASS or during this study).

Eligibility Criteria:
Inclusion Criteria:

* Ability to provide written informed consent and comply with study assessments for the full duration of the study
* Age \> 50 years
* Naïve wet-AMD within 4 months of disease onset (for GALLEY patients) and within 3 months of disease onset for all others
* Patients that have lost \> 5 letters from baseline best vision
* BCVA 20/25-20/320

Exclusion Criteria:

* Pregnancy (positive pregnancy test) or lactation
* Premenopausal women not using adequate contraception. The following are considered effective means of contraception: surgical sterilization or use of oral contraceptives, barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel, an IUD, or contraceptive hormone implant or patch.
* Any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated
* Participation in another simultaneous medical investigation or trial which includes an intervention (Patients could be participating in a non-interventional study such as the GALLEY study)
* Juxtafoveal and extrafoveal wet-AMD
Clinical and Biological Sample Database of Chinese Elderly Patients With Multiple Diseases

The investigators aim to establish a clinical database and biobank for elderly patients with multiple diseases. The collected data will include demographic information, comorbidity characteristic, FRAIL scale, age-adjusted Charlson comorbidity index, relevant blood tests, the results of imaging examination, prescription of drugs, length of hospital stay, number of overall rehospitalizations and death. With this database, the investigators intend to formulate an individualized treatment strategy for these patients.

According to the China Health and Aging Tracking Survey, a significant proportion of elderly individuals aged over 65 suffer from two or more chronic diseases, with prevalence rates ranging from 22.5% to 47.5%. However, due to the decentralized storage of health data, lack of standardization, and collaboration barriers, it is challenging to make use of this information in a meaningful way.Therefore, there is an urgent need to overcome the technical challenges and build an intelligent diagnosis and treatment system for this vulnerable population.

To achieve this goal, it is necessary to establish a clinical database and biobank that includes data on all elderly patients with multimorbidity. This will enable researchers to conduct clinical research on various factors, including clinical and biological predictors of adverse events such as emergency visits, strokes, heart failure, myocardial infarction, tumors, and acute chronic obstructive pulmonary disease. Additionally, the database will facilitate the development of systematic and individualized evaluation tools for elderly patients with multimorbidity, identify prognostic factors that improve short- and long-term outcomes, and enable the participation in multi-center trials at the national or international level. Ultimately, this effort will help establish clinical database and biobank data collection standards for future studies.

Eligibility Criteria:
Inclusion Criteria:

* (1) written and informed consent, (2) participants aged 18 years or older.

Exclusion Criteria:

* (1) Unwilling to participate in the study, (2) Unable or unwilling to cooperate with the baseline or follow-up data collection.
Moderating the Negative Impact of Abnormal Screening Mammograms

This project evaluates the impact of CHESS-Mammo by assessing participants' health information competence, psychological distress, and satisfaction with their doctor as measured by previously validated survey questionnaires.

The study consists of two parts. Part 1 (focus groups) interviewed 11 women in total (6 diagnosed with breast cancer and 5 diagnosed with benign breast disease) reinforced the need for online information during the breast diagnostic process. The focus group reviewed online CHESS-Mammo module and suggested minor changes to content. Part 2 (Evaluation) will enroll 130 women in study and compare one group (65 participants) who receives access to CHESS-Mammo to another group of women (65 participants) who receive an email message containing screening mammography information. Both groups in Part 2 will be evaluated for health information competence, psychological distress, and patient satisfaction with physician through questionnaires. An evaluation of the group that accesses the CHESS-Mammo website will be done. The reason for conducting part 2 of this study is to allow greater insight into the clinical application of a novel Interactive Cancer Communication Systems (CHESS-Mammo) early in the diagnostic workup of breast cancer. By doing this project, we may achieve an important new way of implementing CHESS-Mammo in the clinic.

Eligibility Criteria:
Inclusion Criteria:

To be eligible for the study, subjects must:

* Be females at least 18 years of age,
* Have had their screening mammogram performed at the UW Breast Center,
* Be able to read and write English at the 6th grade level (as shown by their, ability to understand the informed consent),
* Have access to a computer with internet capability.

Exclusion Criteria:

Exclusion Criteria:

* Illiterate
* Homeless
Inpatient Versus Outpatient Foley Cervical Ripening Study

To compare the efficacy and safety of cervical ripening with transcervical Foley catheter in inpatient vs outpatient setting

The aim of the current study is to compare the efficacy and safety of cervical ripening with transcervical Foley catheter in inpatient vs outpatient setting in a diverse, urban population within the United States. We hypothesize that there will be no differences in time-to-delivery, failed induction rates, cesarean section rates, or maternal/neonatal morbidity and that there will be no differences in total length of stay (LOS), hours of sleep, active labor duration, and perceived satisfaction between groups.

Eligibility Criteria:
Inclusion Criteria:

* Indication for Induction of Labor is present
* Gestational age \> 37 completed weeks with absence of comorbidities with an optimal dating (ultrasonography was performed before 22 weeks gestation)
* Singleton fetus in cephalic presentation confirmed with an ultrasound at the time of presentation for induction of labor
* Cervical exam with Bishop Score \<6
* Intact membranes
* Normal vital signs (blood pressure \< 140/90, normal body temperature) at the time of presentation for Induction of Labor and within the last 24 hours
* Maternal age ≥18 years of age

Exclusion Criteria:

* Any contraindication for vaginal birth by institutional policy
* Multiple gestation
* History of cesarean delivery
* Oligohydramnios/polyhydramnios/anhydramnios (MVP \<2cm)
* Rupture of membranes
* Poorly controlled diabetes (Hgb A1C\>8% and/or fingerstick glucose above target \>50% of the time in the past week)
* Poorly controlled chronic hypertension, gestational hypertension or preeclampsia (patient requiring IV antihypertensives within 4 hours of arrival)
* Vaginal bleeding
* Any conditions that require continuous electronic fetal monitoring either by institutional policy or provider determination (intrahepatic cholestasis of pregnancy, intrauterine growth restriction, abnormal non-stress test, others)
* Fetal anomaly with anticipated neonatal intensive care unit admission
* Fetal demise
* HIV infection, presence of genital herpetic lesion
* History of substance abuse during this pregnancy
* History of precipitous delivery (delivery \<3hrs from onset of labor)
* Poor access to care (social, distance to hospital \> 45 min, limited transportation)
* Poor social situation, history of domestic violence, untreated/uncontrolled psychiatric condition
* Inability to give informed consent, history of mental retardation
* Strong preference for inpatient management
* Inability to understand English or Spanish
Petro-trigeminal Line and Petrous Apex Cephaloceles

cephaloceles are rare lesions of the petrous apex, inconsistently listed as meningoceles or arachnoid cysts. They're consistent with a herniation posterolateral of the Meckel cavum within the petrous apex. These lesions may be the cause of a symptomatology varied, or be discovered by chance in subjects who have not been asymptomatic. Currently, there is no evidence in the literature a simple, fast and reproducible radiological marker that allows for the diagnosis of cephaloceles of the petrous apex, in particular the small ones. The purpose of this study is to validate a radiological benchmark simple and reproducible, the trigeminal petrol line, in order to improve the diagnosis of petrous apex cephaloceles


Eligibility Criteria:
Inclusion criteria:

* Major subjects (≥18 years old)
* patients who underwent an MRI with high resolution 3D T2 sequence between 01/01/2003 and 09/31/2020:
* 200 patients consulting for ENT pathology such as vertigo
* 9 patients presenting the radiological criteria in MRI of a cephalocele of the petrous apex according to the current data of the literature on a T2 3D HR sequence
* - Subject who has not expressed his opposition, after being informed, to the reuse of his data for the purposes of this research.

Exclusion criteria:

* Subject who expressed their opposition to participating in the study
* Kinetic Artifacts
* Subject under guardianship or curatorship
* Subject under safeguard of justice
High Dose IV Iron Plus ESA in Chemotherapy-induced Anemia

This study is a multicenter, prospective, randomized phase 3 clinical study comparing the efficacy and safety of the combination treatment of ESA and high-dose IV iron (darbepoietin alfa + ferric derisomaltose/iron isomaltoside) with ESA monotherapy (darbepoietin alfa alone) in CIA patients with functional iron deficiency.


Eligibility Criteria:
Inclusion Criteria:

* Patient who has signed a written consent

  * Age ≥ 19 ③ Histologically diagnosed advanced/metastatic solid cancer

    * Patients who have received myelosuppressive chemotherapy for palliative purposes within 1 month of participating in the study and plan to proceed with chemotherapy while participating in this study
    * Anemia with functional iron deficiency

      1. Hemoglobin \<10g/dL
      2. functional iron deficiency: transferrin saturation \<50% AND serum ferritin 30-800ng/mL ⑤ ECOG performance status 0-2 ⑥ life expectancy ≥ 24weeks

         Exclusion Criteria:
* Absolute iron deficiency (serum ferritin \<30 ng/mL AND transferrin saturation \<20%) or no iron deficiency (serum ferritin ≥800 ng/mL OR transferrin saturation ≥50%)

  * If there is another cause of anemia other than chemotherapy-induced anemia (eg, vitamin B12 or folic acid deficiency, hemolytic anemia, myelodysplastic syndrome, etc.)

    * Ongoing bleeding at the time of study registration

      * Patients who require rapid blood transfusion at the time of study registration (eg, rapidly progressing anemia)

        * Presence of bone marrow tumor invasion

          * Receiving erythropoiesis stimulating agents within 3 weeks of study registration or have a history of oral or intravenous iron administration or blood transfusion within 2 weeks of study registration

            * History of venous thromboembolism within 6 months or taking anticoagulants at the time of study registration

              * Past or family history of hemochromatosis ⑨ History of hypersensitivity to iron treatment or erythropoiesis stimulating agents ⑩ Uncontrolled acute or chronic infection ⑪ Renal dysfunction (serum creatinine ≥2.0 mg/dL, or glomerular filtration rate \<30 mL/min/1.73 m2) or liver dysfuction (AST or ALT 3 times or more the upper limit of normal) ⑫ Pregnant or lactating women
Investigation of Acute Mood and Cognitive Performance Effects of Beverages Containing Phenolics in Healthy Adults

An acute, randomized, placebo controlled, double blinded crossover study in health subjects. Participants will complete 4 intervention arms in random order consisting of a placebo control beverage, a high dose phenolic beverage, a high dose phenolic beverage combined with a fruit extract, and a low does phenolic beverage. The primary objective of the study is to assess the effects of the phenolic compounds, at two different levels, alone and in combination with a fruit extract, on mood and cognitive performance during extended periods of cognitively demanding task performance.


Eligibility Criteria:
Inclusion Criteria:

* Aged 18 to 49 years
* Self-report of good health
* Are not excluded on the basis of the following exclusion criteria

Exclusion Criteria:

* Are a smoker
* Have food allergies or sensitivities to any of the ingredients contained in the investigational product or any other foodstuff
* Currently take medication except the contraceptive pill
* Have habitually used dietary supplements within the last month (defined as more than 3 consecutive days or 4 days in total)
* Have sleep disturbances and/or are taking sleep aid medication Are employed in a job that includes night shift work
* Have a Body Mass Index (BMI) outside of the range 18-35 kg/m2or weigh less than 50kg or more than 85kg.
* Have high blood pressure (systolic over 139 mm Hg or diastolic over 89 mm Hg)
* Have a history of neurological, vascular or psychiatric illness including epilepsy or seizures (excluding depressive illness and anxiety)
* Have a history of anxiety or a current diagnosis of anxiety or depression
* Are pregnant, trying to get pregnant or breast feeding
* Have a recent history of (within 12 months of screening visit) or strong potential for alcohol or substance abuse. Alcohol abuse is defined as more than 60g (men) / 40g (women) pure alcohol per day (7 / 5.5 units)
* Have learning difficulties or dyslexia
* Have visual impairment that cannot be corrected with glasses or contact lenses
* Have frequent migraines that require medication (more than or equal to 1 per month)
* Have disorders of the blood (e.g. anaemia, hemophilia, thrombocytosis)
* Have a heart disorder or a history of vascular illness
* Have a respiratory disorder that requires regular medication (Note: participants with asthma who only take their medication occasionally/as required are eligible for this study)
* Have a diagnosis of type I or type II diabetes
* Have a history of renal or hepatic disease, or other severe diseases of the gastrointestinal tract (e.g. iron accumulation, iron utilization disorders, hypercalcaemia, hypercalciuria), that are likely to interfere with metabolism/absorption/secretion of the product under investigation
* Have any health condition that would prevent fulfillment of the study requirements
* Are currently or have in the past 8weeks participated in other clinical or nutrition intervention studies
* Have participated in the BPNRC's recent stress study
* Do not have a bank account (required for payment)
Comparison of Pre-test Probability Model for Heparin-induced Thrombocytopenia in Post-operative Cardiac Surgery

Heparin-induced thrombocytopenia (HIT) is a pro-thrombotic immunological condition that occurs in some patients exposed to heparin. The incidence of HIT is estimated at 0.1 to 0.3% of patients exposed to heparin, and rises to 3% in postoperative cardiac surgery. Cardiac surgery under CEC requires the use of high doses of heparin, which contributes to the increased incidence of HIT in this population. This high incidence is also explained by the comorbid profile of cardiac surgery patients, who often present risk factors for HIT (perioperative context, atrial fibrillation, organ failure, previous exposure to heparin, etc.). When it occurs postoperatively in cardiac surgery, there is a 28% increase in mortality, a 50% increase in morbidity, and an increase in hospitalization costs and length of stay. Although usually detected in medical wards on the basis of probability scores (4T, HEP), its diagnosis is less easy in postoperative cardiac surgery. Because of the many differential diagnoses, the screening scores usually used are less effective, and HIT is often diagnosed late, in patients who may have already developed a thromboembolic complication, which sometimes proves fatal. In addition, the diagnostic tests for HIT are compromised and lose their sensitivity in postoperative cardiac surgery, given the high incidence of seroconversion observed after extracorporeal circulation. Indeed, more than 50% of patients have antibodies to PF4/heparin, but only 1 to 2% of them have true HIT.These elements highlight the need to develop effective screening scores for HIT in postoperative cardiac surgery, given the complications to which patients are exposed in the event of underdiagnosis but also in the event of overdiagnosis. Other screening scores are being studied, not yet validated in cardiac surgery, such as the CPB score or the GFHT score. Early recognition of HIT would reduce the morbidity and mortality associated with this condition.

The present study should make it possible to identify the most effective HIT probability score among those used in routine screening and thus to orient towards screening for this condition as early as possible, and consequently reduce the associated morbidity.


Eligibility Criteria:
Inclusion Criteria:

* Major patients, who underwent cardiac surgery with cardiopulmonarybypass between 01/01/2010 and 12/31/2021, in whom HIT was suspected postoperatively.

Exclusion Criteria:

* Patients with known preoperative HIT,
* cardiac surgery patients without bypass surgery,
* diagnostic tests for HIT not performed.